You Position: Home > Paper
Clinical Analysis of Uncommon Epidermal Growth Factor Receptor Mutations in 16 Cases of Nonsmall Cell Lung Cancer
( views:19, downloads:20 )
- Author:
- No author available
- Journal Title:
- Chinese Medical Journal
- Issue:
- 8
- DOI:
- 10.4103/0366-6999.229887
- Key Word:
- No keyword available
Abstract： To the Editor:Epidermal growth factor receptor (EGF R) is overexpressed in non-small cell lung cancer (NSCLC) and contains a tyrosine kinase inhibitor (TKI) domain which acts as an important therapeutic target.Previous studies have observed the efficacy of EGFR-TKIs in the most commonly targeted exon mutations (19 and 21).This study was to investigat the pathologic features of uncommon EGFR mutations and the clinical efficacies of EGFR-TKIs treatment.
- [1]Zhou C,Wu YL,Chen G,etc.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.[J].2011,12(8).
- [2]Rosell R,Moran T,Queralt C.Screening for epidermal growth factor receptor mutations in lung cancer.[J].2009,361(10).